Tuberculosis in South‑East Asia: a test of systems, solidarity and sustained political will
A stubborn public‑health threat
Tuberculosis (TB) continues to exact a heavy toll across the World Health Organization’s South‑East Asia Region (SEARO), despite decades of dedicated control programmes. Globally, WHO estimated roughly 10.6 million people developed TB in 2022, with more than a million lives lost. A substantial portion of that burden falls in South‑East Asia: populous, densely settled countries such as India, Indonesia and Bangladesh account for many of the region’s cases, while smaller nations face distinct access and equity barriers. Emerging drug‑resistant strains, persistent diagnostic and treatment gaps, and fragile financing imperil progress toward the global End TB targets. The trajectory of the epidemic in the coming years will reflect not only technical fixes but also political choices about resources, integration and rights.
Recalibrating priorities: what SEARO is accelerating now
The WHO South‑East Asia Regional Office (SEARO) is championing an intensified, systems‑focused response to close weak links across the TB care continuum – from faster detection to uninterrupted therapy and prevention. The current emphasis is on scaling rapid diagnostics, delivering shorter and better‑tolerated regimens, digitizing patient pathways, and securing predictable funding. Priority actions being expanded region‑wide include:
– Faster case detection: placing WHO‑recommended rapid molecular tests and point‑of‑care diagnostics into primary clinics and private providers to reduce the interval between symptom onset and diagnosis.
– Prioritizing high‑risk groups: concentrating screening and tailored support for migrants, slum and informal‑settlement residents, miners, people living with HIV and other vulnerable cohorts.
– Simplifying and shortening treatment: adopting shorter, more tolerable regimens for both drug‑susceptible and drug‑resistant TB to improve adherence and outcomes.
– Digital modernization: rolling out e‑notification, interoperable surveillance dashboards, adherence apps and telemedicine to strengthen continuity of care and supply‑chain visibility.
– Sustainable financing: mobilizing domestic budgets alongside donor support to prevent stockouts of drugs and cartridges and to protect community outreach during economic shocks.
Measurable regional goals to 2027
SEARO countries have agreed quantifiable milestones to guide efforts over the next three years:
– Case notification: register at least 90% of the region’s estimated TB cases.
– Drug‑resistant TB treatment: start at least 80% of eligible people on appropriate regimens.
– Preventive therapy: provide TB preventive treatment (TPT) to a minimum of 30 million people across the region.
– Mortality reduction: reduce TB deaths by at least 65% relative to 2015 levels.
Achieving these targets will require stronger governance and multisectoral accountability, updated national strategies aligned with WHO guidance, and integration of TB services into universal health coverage reforms. Equally important is formalizing the participation of civil society and survivor networks in planning and monitoring to address stigma, catastrophic costs and rights protections.
Technology plus community: the operational frontlines
Countries in South‑East Asia are pairing innovations with community‑based approaches to move diagnosis, treatment and support closer to people’s homes. Rather than depending solely on tertiary hospitals, programmes are decentralizing services, strengthening primary‑level capacity, and mobilizing trusted local actors.
How this plays out in practice
– Rapid molecular platforms at the edge: Deploying cartridge‑based molecular assays in urban clinics and remote health posts shortens the diagnostic cascade, allowing treatment to start within days rather than weeks.
– Real‑time programme intelligence: Electronic case‑based surveillance and interoperable dashboards give district teams near real‑time visibility into case clusters, treatment outcomes and commodity stocks, enabling faster corrective action.
– AI‑assisted triage: Automated chest X‑ray interpretation tools are being used in busy primary care settings to triage patients for confirmatory testing, increasing throughput and saving clinician time.
– Digital adherence and remote care: SMS reminders, smartphone adherence apps and teleconsultations complement home visits to reduce missed doses and loss to follow‑up.
– Community networks and peer support: Trained volunteers, community health workers and survivor groups conduct door‑to‑door screening, monitor treatment at home, and help patients access social protection and transport support.
Illustrative operational lessons
– Mobile diagnostic vans in densely populated informal settlements have consistently detected more bacteriologically confirmed TB than passive facility‑based approaches, demonstrating the value of outreach.
– Electronic stock‑monitoring systems have prevented localized stockouts by forecasting shortages and triggering redistributions of drugs and testing cartridges.
– During recent climate events and pandemic disruptions, community treatment supporters and local health committees were pivotal in maintaining continuity of care by delivering medicines, arranging remote consultations, and coordinating emergency referrals.
Equity and disaggregated data as guiding principles
A central theme in regional guidance is the use of person‑level, disaggregated data to ensure no groups are left behind. Breaking indicators by age, sex, socio‑economic status and migration status helps reveal who is missed by routine services. Delivering people‑centred care through neighbourhood clinics, mobile units and trusted community providers is critical to closing coverage and outcome gaps.
Current context and trends to watch
Although technical tools and community networks are strengthening, the epidemic’s future depends on political commitment and financing. The growing availability of shorter regimens for drug‑resistant TB, wider adoption of digital platforms, and maturation of community systems present historic opportunities – but only if countries protect core programmes from fiscal retrenchment and integrate TB into broader health reforms. High‑burden countries in SEARO will continue to dominate regional case counts, but progress in smaller states will be equally important for regional elimination ambitions.
Concrete actions for governments and partners
– Bring diagnostics where people seek care: prioritize placement of rapid molecular and point‑of‑care tests in primary‑level and private sector settings.
– Target the left‑behind: design active case‑finding strategies for migrants, slum populations, miners and others at elevated risk.
– Make preventive therapy accessible: expand eligibility and simplify delivery of TPT through primary care and community channels.
– Invest in interoperable digital infrastructure: standardize indicators, adopt open‑source platforms and protect privacy to enable timely, targeted responses.
– Secure predictable financing: ensure domestic budget lines and donor commitments cover essential medicines, diagnostics and community outreach so programs can withstand shocks.
– Institutionalize community leadership: give survivor networks and civil society formal roles in planning, budgeting and monitoring to tackle stigma, financial barriers and rights violations.
Why the next few years are decisive
SEARO’s experience underscores a basic truth: when political commitment, technical innovation and community engagement converge, rapid gains are possible. But momentum is fragile. Choices made now about financing, integration, innovation uptake and reaching marginalized populations will determine whether South‑East Asia reverses recent stagnation and accelerates toward the End TB goals. Success here will not only protect millions of lives in the region but will also serve as a blueprint for global TB elimination.